- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
GI Cancers | Clinical
Guidelines for Gastric and Esophageal Cancers Expand to Include NGS, Immunotherapies
May 15, 2021
The latest updates on gastric and esophageal cancers focus on greater use of biomarkers, next-generation sequencing (NGS), and immunotherapies.
Roundtable Discussion: Ajani Leads Debate on Molecular Testing in Gastric Cancer
May 12, 2021
Jaffer A. Ajani, MD led a discussion around biomarkers to consider when determining systemic therapy for patients with stage IV gastric adenocarcinoma.
FDA Grants Orphan Drug Status to BOLD-100 For the Treatment of Gastric Cancer
May 11, 2021
The FDA has granted orphan drug designation to the first-in-class ruthenium-based small molecule, BOLD-100, for the treatment of patients with gastric cancer.
FDA Approves 1L Pembrolizumab Combination in Locally Advanced Unresectable or Metastatic HER2+ Gastric/GEJ Cancers
May 05, 2021
The FDA has granted accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction cancer.
FDA Grants Priority Review to Ivosidenib Tablets for IDH1-Mutant Cholangiocarcinoma
May 05, 2021
The FDA accepted a supplemental new drug application for ivosidenib tablets and granted it priority review for the treatment of patients with previously treated IDH1-mutated cholangiocarcinoma.
FDA Approval Sought for Surufatinib in Pancreatic and Extra-Pancreatic NETs
May 03, 2021
A rolling submission of a new drug application to the FDA has been initiated for surufatinib as a potential treatment option for patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Johns Reflects on Landmark Studies for Esophageal Cancer Awareness Month
April 30, 2021
In an interview with Targeted Oncology, Mark E. Johns, MD, discussed landmark esophageal cancer studies, newly approved treatments, and the future of the space.
FGFR Inhibitors Make Inroads in Cholangiocarcinoma
April 24, 2021
Although chemotherapy is the mainstay of systemic treatment for advanced cholangiocarcinoma, there are limited treatment options when the disease progresses
FDA Grants Breakthrough Therapy Designation to Bemarituzumab for Select FGFR2b+/HER2- Advanced Gastric and GEJ Cancers
April 20, 2021
The FDA has granted breakthrough therapy designation to bemarituzumab for the first-line treatment of patients with HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma who harbor FGFR2b overexpression or amplification.
FDA Lifts Partial Clinical Hold from Study of SBP-101 in Pancreatic Cancer
April 16, 2021
The FDA has lifted a partial clinical hold on a phase 1 clinical trial of SBP-101 in combination with the standard-of-care agents gemcitabine and nab-paclitaxel as treatment of patients with metastatic pancreatic ductal adenocarcinoma.